572 related articles for article (PubMed ID: 30058046)
21. CFH and CFB mutations in Shiga toxin-associated haemolytic uraemic syndrome in a 6-year-old boy.
Çelakil ME; Yücel BB; Bek K
Paediatr Int Child Health; 2020 May; 40(2):129-131. PubMed ID: 31242818
[TBL] [Abstract][Full Text] [Related]
22. Paediatric haemolytic uraemic syndrome related to Shiga toxin-producing
Bruyand M; Mariani-Kurkdjian P; Le Hello S; King LA; Van Cauteren D; Lefevre S; Gouali M; Jourdan-da Silva N; Mailles A; Donguy MP; Loukiadis E; Sergentet-Thevenot D; Loirat C; Bonacorsi S; Weill FX; De Valk H;
Euro Surveill; 2019 Feb; 24(8):. PubMed ID: 30808442
[TBL] [Abstract][Full Text] [Related]
23. Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.
Zoja C; Buelli S; Morigi M
Pediatr Nephrol; 2019 Mar; 34(3):379-388. PubMed ID: 29214442
[TBL] [Abstract][Full Text] [Related]
24. Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review.
de Zwart PL; Mueller TF; Spartà G; Luyckx VA
Pediatr Nephrol; 2024 May; 39(5):1369-1385. PubMed ID: 38057431
[TBL] [Abstract][Full Text] [Related]
25. STEC-HUS, atypical HUS and TTP are all diseases of complement activation.
Noris M; Mescia F; Remuzzi G
Nat Rev Nephrol; 2012 Nov; 8(11):622-33. PubMed ID: 22986360
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial.
Garnier A; Brochard K; Kwon T; Sellier-Leclerc AL; Lahoche A; Launay EA; Nobili F; Caillez M; Taque S; Harambat J; Michel-Bourdat G; Guigonis V; Fila M; Cloarec S; Djamal-Dine D; de Parscaux L; Allard L; Salomon R; Ulinski T; Frémeaux-Bacchi V; Morin C; Olivier-Abbal P; Colineaux H; Auriol F; Arnaud C; Kieffer I; Brusq C
J Am Soc Nephrol; 2023 Sep; 34(9):1561-1573. PubMed ID: 37303085
[TBL] [Abstract][Full Text] [Related]
27. Decreased severity of Shiga toxin-producing
Geramita MA; Hofer J; Cooper J; Moritz ML
BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28855217
[TBL] [Abstract][Full Text] [Related]
28. Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab.
Ağbaş A; Göknar N; Akıncı N; Yıldırım ZY; Taşdemir M; Benzer M; Gökçe İ; Candan C; Küçük N; Uzuner S; Özçelik G; Demirkol D; Sever L; Çalışkan S
Pediatr Nephrol; 2018 Dec; 33(12):2371-2381. PubMed ID: 30159625
[TBL] [Abstract][Full Text] [Related]
29. Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome.
Keir LS; Saleem MA
Pediatr Nephrol; 2014 Oct; 29(10):1895-902. PubMed ID: 23843163
[TBL] [Abstract][Full Text] [Related]
30. Virulence factors of Shiga toxin-producing Escherichia coli and the risk of developing haemolytic uraemic syndrome in Norway, 1992-2013.
Naseer U; Løbersli I; Hindrum M; Bruvik T; Brandal LT
Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1613-1620. PubMed ID: 28391537
[TBL] [Abstract][Full Text] [Related]
31. Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.
Verhave JC; Wetzels JF; van de Kar NC
Nephrol Dial Transplant; 2014 Sep; 29 Suppl 4():iv131-41. PubMed ID: 25165180
[TBL] [Abstract][Full Text] [Related]
32. Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients.
Terano C; Ishikura K; Hamada R; Yoshida Y; Kubota W; Okuda Y; Shinozuka S; Harada R; Iyoda S; Fujimura Y; Hamasaki Y; Hataya H; Honda M
Nephrology (Carlton); 2018 Jun; 23(6):539-545. PubMed ID: 28387984
[TBL] [Abstract][Full Text] [Related]
33. Shiga toxin-producing Escherichia coli O171:H25 strain isolated from a patient with haemolytic uraemic syndrome.
Lepšanović Z; Opačić D; Lazić S; Herpay M; Tóth S; Kostić M; Kucsera I
Acta Microbiol Immunol Hung; 2012 Jun; 59(2):215-24. PubMed ID: 22750781
[TBL] [Abstract][Full Text] [Related]
34. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).
Exeni RA; Fernandez-Brando RJ; Santiago AP; Fiorentino GA; Exeni AM; Ramos MV; Palermo MS
Pediatr Nephrol; 2018 Nov; 33(11):2057-2071. PubMed ID: 29372302
[TBL] [Abstract][Full Text] [Related]
35. HUS and the case for complement.
Conway EM
Blood; 2015 Oct; 126(18):2085-90. PubMed ID: 26396094
[TBL] [Abstract][Full Text] [Related]
36. Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli-associated paediatric haemolytic uraemic syndrome.
Ahlenstiel-Grunow T; Hachmeister S; Bange FC; Wehling C; Kirschfink M; Bergmann C; Pape L
Nephrol Dial Transplant; 2016 Jul; 31(7):1114-21. PubMed ID: 27190382
[TBL] [Abstract][Full Text] [Related]
37. Atypical hemolytic uremic syndrome: a clinical conundrum.
Bajracharya P; Jain A; Baracco R; Mattoo TK; Kapur G
Pediatr Nephrol; 2016 Oct; 31(10):1615-24. PubMed ID: 27139899
[TBL] [Abstract][Full Text] [Related]
38. Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999-2008.
Jenssen GR; Vold L; Hovland E; Bangstad HJ; Nygård K; Bjerre A
BMC Infect Dis; 2016 Jun; 16():285. PubMed ID: 27297224
[TBL] [Abstract][Full Text] [Related]
39. CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS).
Caillaud C; Zaloszyc A; Licht C; Pichault V; Frémeaux-Bacchi V; Fischbach M
Pediatr Nephrol; 2016 Jan; 31(1):157-61. PubMed ID: 26399238
[TBL] [Abstract][Full Text] [Related]
40. Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2.
Wijnsma KL; Schijvens AM; Rossen JWA; Kooistra-Smid AMDM; Schreuder MF; van de Kar NCAJ
Pediatr Nephrol; 2017 Jul; 32(7):1263-1268. PubMed ID: 28343354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
